223 related articles for article (PubMed ID: 16556892)
41. Post-remission therapy of adult acute myeloid leukaemia: one cycle of high-dose versus standard-dose cytarabine. Leukaemia Project Group of the Swiss Group for Clinical Cancer Research (SAKK).
Fopp M; Fey MF; Bacchi M; Cavalli F; Gmuer J; Jacky E; Schmid L; Tichelli A; Tobler A; Tschopp L; Von Fliedner V; Gratwohl A
Ann Oncol; 1997 Mar; 8(3):251-7. PubMed ID: 9137794
[TBL] [Abstract][Full Text] [Related]
42. Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group.
Kobayashi T; Miyawaki S; Tanimoto M; Kuriyama K; Murakami H; Yoshida M; Minami S; Minato K; Tsubaki K; Ohmoto E; Oh H; Jinnai I; Sakamaki H; Hiraoka A; Kanamaru A; Takahashi I; Saito K; Naoe T; Yamada O; Asou N; Kageyama S; Emi N; Matsuoka A; Tomonaga M; Ohno R
J Clin Oncol; 1996 Jan; 14(1):204-13. PubMed ID: 8558199
[TBL] [Abstract][Full Text] [Related]
43. Anti-Leukemic Properties of Histamine in Monocytic Leukemia: The Role of NOX2.
Kiffin R; Grauers Wiktorin H; Nilsson MS; Aurelius J; Aydin E; Lenox B; Nilsson JA; Ståhlberg A; Thorén FB; Hellstrand K; Martner A
Front Oncol; 2018; 8():218. PubMed ID: 29967760
[TBL] [Abstract][Full Text] [Related]
44. Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia.
Sander FE; Rydström A; Bernson E; Kiffin R; Riise R; Aurelius J; Anderson H; Brune M; Foà R; Hellstrand K; Thorén FB; Martner A
Oncotarget; 2016 Feb; 7(7):7586-96. PubMed ID: 26863635
[TBL] [Abstract][Full Text] [Related]
45. Long-term follow-up of relapsed acute leukemia treated with immunotherapy after allogeneic transplantation: the inseparability of graft-versus-host disease and graft-versus-leukemia, and the problem of extramedullary relapse.
Singhal S; Powles R; Kulkarni S; Treleaven J; Saso R; Mehta J
Leuk Lymphoma; 1999 Feb; 32(5-6):505-12. PubMed ID: 10048423
[TBL] [Abstract][Full Text] [Related]
46. Long-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single Center Retrospective Analysis.
Helbig G; Koclęga A; Woźniczka K; Kopera M; Kyrcz-Krzemień S
Pathol Oncol Res; 2018 Jul; 24(3):469-475. PubMed ID: 28660547
[TBL] [Abstract][Full Text] [Related]
47. Complete remission after the first cycle of induction chemotherapy determines the clinical efficacy of relapse-preventive immunotherapy in acute myeloid leukaemia.
Nilsson MS; Hallner A; Brune M; Nilsson S; Thorén FB; Martner A; Hellstrand K
Br J Haematol; 2020 Feb; 188(4):e49-e53. PubMed ID: 31853942
[No Abstract] [Full Text] [Related]
48. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience.
Sierra J; Storer B; Hansen JA; Martin PJ; Petersdorf EW; Woolfrey A; Matthews D; Sanders JE; Storb R; Appelbaum FR; Anasetti C
Bone Marrow Transplant; 2000 Aug; 26(4):397-404. PubMed ID: 10982286
[TBL] [Abstract][Full Text] [Related]
49. Role of postinduction immunotherapy in acute myeloid leukemia.
Klingemann HG
Leukemia; 1996 Apr; 10 Suppl 1():S21-2. PubMed ID: 8618464
[TBL] [Abstract][Full Text] [Related]
50. Interleukin-2 after autologous stem-cell transplantation for adult patients with acute myeloid leukemia in first complete remission.
Stein AS; O'Donnell MR; Slovak ML; Snyder DS; Nademanee AP; Parker P; Molina A; Somlo G; Fung HC; Krishnan A; Rodriguez R; Spielberger RT; Wang S; Dagis A; Vora N; Arber DA; Niland JC; Forman SJ
J Clin Oncol; 2003 Feb; 21(4):615-23. PubMed ID: 12586797
[TBL] [Abstract][Full Text] [Related]
51. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.
Kern W; Haferlach T; Schoch C; Loffler H; Gassmann W; Heinecke A; Sauerland MC; Berdel W; Buchner T; Hiddemann W
Blood; 2003 Jan; 101(1):64-70. PubMed ID: 12393605
[TBL] [Abstract][Full Text] [Related]
52. Interleukin-2 for the treatment of advanced acute myelogenous leukemia patients with limited disease: updated experience with 20 cases.
Meloni G; Vignetti M; Andrizzi C; Capria S; Foa R; Mandelli F
Leuk Lymphoma; 1996 May; 21(5-6):429-35. PubMed ID: 9172807
[TBL] [Abstract][Full Text] [Related]
53. The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission.
Blaise D; Attal M; Pico JL; Reiffers J; Stoppa AM; Bellanger C; Molina L; Nedellec G; Vernant JP; Legros M; Gabus R; Huguet F; Brandely M; Hercend T; Olive D; Maraninchi D
Leuk Lymphoma; 1997 May; 25(5-6):469-78. PubMed ID: 9250817
[TBL] [Abstract][Full Text] [Related]
54. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
[TBL] [Abstract][Full Text] [Related]
55. Conventional chemotherapy for acute myeloid leukemia: a Brazilian experience.
Pagnano KB; Traina F; Takahashi T; Oliveira GB; Rossini MS; Lorand-Metze I; Vigorito AC; Miranda EC; De Souza CA
Sao Paulo Med J; 2000 Nov; 118(6):173-8. PubMed ID: 11120548
[TBL] [Abstract][Full Text] [Related]
56. Interleukin-2 therapy in relapsed acute myelogenous leukemia.
Meloni G; Vignetti M; Pogliani E; Invernizzi R; Allione B; Mirto S; Sica S; Leoni F; Selleri C; Mandelli F
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S43-7. PubMed ID: 9457393
[TBL] [Abstract][Full Text] [Related]
57. Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia.
Bradstock KF; Link E; Di Iulio J; Szer J; Marlton P; Wei AH; Enno A; Schwarer A; Lewis ID; D'Rozario J; Coyle L; Cull G; Campbell P; Leahy MF; Hahn U; Cannell P; Tiley C; Lowenthal RM; Moore J; Cartwright K; Cunningham I; Taper J; Grigg A; Roberts AW; Benson W; Hertzberg M; Deveridge S; Rowlings P; Mills AK; Gill D; Bardy P; Campbell L; Seymour JF;
J Clin Oncol; 2017 May; 35(15):1678-1685. PubMed ID: 28368672
[TBL] [Abstract][Full Text] [Related]
58. Treatment of acute myeloid leukaemia patients with recombinant interleukin 2: a pilot study.
Foa R; Meloni G; Tosti S; Novarino A; Fenu S; Gavosto F; Mandelli F
Br J Haematol; 1991 Apr; 77(4):491-6. PubMed ID: 2025574
[TBL] [Abstract][Full Text] [Related]
59. Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol.
Oriol A; Ribera JM; Esteve J; Guàrdia R; Brunet S; Bueno J; Pedro C; Llorente A; Tormo M; Besalduch J; Sánchez JM; Batlle M; Vivancos P; Carreras E; Vilà JM; Julià A; Sierra J; Montserrat E; Feliu E;
Haematologica; 2004 Jul; 89(7):791-800. PubMed ID: 15257930
[TBL] [Abstract][Full Text] [Related]
60. Long-term survival and development of secondary malignancies in patients with acute myeloid leukemia treated with aclarubicin or daunorubicin plus cytosine arabinoside followed by intensive consolidation chemotherapy in a Danish national phase III trial. Danish Society of Haematology Study Group on AML.
de Nully Brown P; Hoffmann T; Hansen OP; Boesen AM; Grønbaek K; Hippe E; Jensen MK; Thorling K; Storm HH; Pedersen-Bjergaard J
Leukemia; 1997 Jan; 11(1):37-41. PubMed ID: 9001416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
